Accesso libero

A Comparative Analysis of the Effects of Haloperidol and Dexmedetomidine on QTc Interval Prolongation during Delirium Treatment in Intensive Care Units

,  e   
31 lug 2024
INFORMAZIONI SU QUESTO ARTICOLO

Cita
Scarica la copertina

Fig. 1

Indications for hospitalization in the intensive care unit.
Indications for hospitalization in the intensive care unit.

Fig. 2

Forest plot graph of the relationship between baseline characteristics of patients and QTc prolongation after drug infusions.
Forest plot graph of the relationship between baseline characteristics of patients and QTc prolongation after drug infusions.

Fig. 3.

A Patients with QTc interval above 450 msec after drug infusions, B: Patients with >20 msec prolongation in QTc interval after drug infusions.
A Patients with QTc interval above 450 msec after drug infusions, B: Patients with >20 msec prolongation in QTc interval after drug infusions.

Fig. 4

The effect of dexmedetomidine (A) and haloperidol (B) treatment on QT and QTc interval in box plot graph.
The effect of dexmedetomidine (A) and haloperidol (B) treatment on QT and QTc interval in box plot graph.

Blood pressure, heart rate, oxygen saturation, sedation depth, and QT interval before and after haloperidol and dexmedetomidine treatment_

Patient characteristics Dexmedetomidine (n=45) Haloperidol (n=45)

Pre-infusion Post-infusion P value Pre-infusion Post-infusion P value
Systolic blood pressure (mmHg) 117.6±3.4 113.2±27.2 0.345 137.5±24.4 117.4±26.0 <0.001*
Heart rate (bpm) 98.5±25.7 100.4±23.1 0.664 97.5±19.7 88.5±27.8 0.014*
Pulse oximeter oxygen saturation (SpO2) (%) 96.2±2.2 96.9±2.3 0.004* 97.2±2.3 97.0±2.2 0.585
Ramsay Sedation scale 1.3±0.8 1.4±0.6 0.204 1.5±1.0 1.8±1.0 0.015*
RASS 2.5±1.5 1.2±1.2 <0.001* 2.0±2.2 0.40±1.5 <0.001*

Patient characteristics according to treatment groups_

Patient characteristics Dexmedetomidine (n=45) Haloperidol (n=45) P value
Age (years) (mean±SD) 77.2±9.0 73.2±15.8 0.14
Sex (male%) 48.9 51.1 0.84
BMI (kg/m2) (mean±SD) 28.0±6.6 28.0±6.9 0.95
APACHE II (mean±SD) 32.8±5.3 32.0±7.0 0.58
GCS (mean±SD) 9.1±2.2 9.4±1.3 0.48
Hospitalization period (day) (median±SD) 16±13 21±34 0.016*
Time to delirium (hour) (median±SD) 48±197 120±146 0.27
Ventilator duration (day) (median±SD) 14±13.4 21±34.7 0.013*
Drug infusion time (hour) (median±SD) 108±95.2 126±75.5 0.94
Total amount of drug (mg) (median±SD) 3.8±1.6 150±107.4 <0.001*
In-hospital mortality (%) 48.9 57.8 0.4
Pre-infusion SBP (mmHg) (mean±SD) 117.5±23.4 137.5±24.4 <0.001*
Pre-infusion HR (bpm) (mean±SD) 98.5±25.6 97.5±19.7 0.83
Pre-infusion SpO2 (mean±SD) 96.2±2.2 97.2±2.3 0.04*
Pre-infusion Ramsay SS (median±SD) 1.3±0.8 1.5±1.0 0.26
Pre-infusion RASS score (median±SD) 2.45±1.45 1.96±2.2 0.18
Pre-infusion QT interval (ms) (mean±SD) 360.5±81.7 363.2±51.1 0.85
Pre-infusion QTc interval (ms) (mean±SD) 409.4±63.1 427.3±45.8 0.99